Liquidia Corp (LQDA) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Welcome to the Jefferies Global Healthcare Conference. My name is Kombe Ziazi. I'm a biotech analyst here at Jefferies. Today, it's my distinct honor and pleasure to welcome Liquidia Therapeutics CEO, Roger Jeffs, and CFO, Mike Caseta. Coming off a recent drug approval for Eutrebia. Welcome gentlemen. Thank you, Combes. Roger, maybe I'll allow you to have some open remarks because Eutrebia was so recently approved. We'd just love to hea ...

Summary of Liquidia's Conference Call Company Overview - **Company**: Liquidia - **Industry**: Biotech, specifically in the cardiopulmonary space - **Lead Product**: Eutrebia, a treatment for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PHILD) [3][12] Key Points and Arguments Product Development and Approval - Liquidia is approaching its PDUFA date for Eutrebia, which is set for May 24, indicating a potential approval for the treatment of PAH and PHILD [3][15] - Eutrebia utilizes proprietary print technology to create a dry powdered formulation of treprostinil, allowing for better lung deposition and tolerability [3][5] - The company has developed five launch strategies, including product profile development, a best-in-class sales force, patient support services, product availability, and payer access [4][5] Market Dynamics - The reference brand, United Therapeutics' Tyvaso, has a sales run rate of approximately $2 billion, with a market characterized by less than 20% penetration in PHILD [19][21] - Liquidia estimates the PHILD market to have around 60,000 patients, presenting significant growth opportunities [21][30] - The PAH market is described as crowded, with Liquidia aiming to position Eutrebia as the first choice among prostacyclins due to its ability to titrate to higher doses [22][23] Competitive Landscape - Liquidia is aware of ongoing litigation from United Therapeutics, which has filed multiple patents against them to delay Eutrebia's market entry [8][11] - The company is confident in its legal position and is committed to providing alternative treatments for patients [12][69] Sales and Marketing Strategy - Liquidia has a 50-person sales force with extensive experience in PAH, focusing on building relationships with healthcare providers [36][38] - The sales force has engaged in unbranded promotional efforts to educate physicians about the product and its technology [38][39] - The company plans to ensure broad access to Eutrebia through relationships with payers, targeting a market mix of approximately 50% Medicare Part D and 35-40% commercial [48][49] Product Differentiation - Eutrebia is designed to be easy to use, requiring no refrigeration and allowing for quick inhalation [51][55] - The device is familiar to pulmonologists, which may facilitate adoption among patients [55][56] - Liquidia emphasizes the importance of patient-reported outcomes and quality of life improvements as key measures of success [58][61] Future Outlook - Liquidia is preparing for a Phase 3 study of L606, a liposomal sustained release formulation, which could provide a once-daily treatment option [64][66] - The company is focused on maximizing the benefits of inhaled treprostinil and is optimistic about its long-term positioning in the market [66] Additional Important Information - Liquidia has been proactive in manufacturing commercial supply in anticipation of approval, ensuring sufficient product availability at launch [44][45] - The company is committed to addressing the needs of patients with PAH and PHILD, aiming to provide effective treatment options [12][69]

Liquidia Corp (LQDA) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Jason Adair - Chief Business OfficerRoger Jeffs - CEOMichael Kaseta - COO & CFOJulian Harrison - Managing DirectorRusty Schundler - General CounselKambiz Yazdi - Vice President - Equity ResearchRajeev Saggar - CMOGreg Harrison - Director - BiotechnologyScott Moomaw - Chief Commercial OfficerChi Fong - VP - Equity ResearchRyan Deschner - Vice President - Equity Research Conference Call Participants Cory Jubinville - Mana ...

Liquidia Corp (LQDA) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome everyone to the Liquidia Corporation First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. My name is Ari, and I will be your conference operator today. Currently, all participants are in a listen only mode. Following the presentation, we will conduct a question and answer session. Intra instructions will be provided at that time for you to queue up for questions. I would ...